Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2023

01-10-2023 | Bevacizumab | Case report

Bevacizumab/pralsetinib

Various toxicity: case report

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Bi Y, et al. Targeted treatments after chemoradiotherapy failure in a patient with relapsed, advanced non-small cell lung cancer with on-therapy circulating tumor biomarker monitoring: A case report. Oncology Letters 26: 1-8, No. 3, 02 Aug 2023. Available from: URL: http://​doi.​org/​10.​3892/​ol.​2023.​13993
Metadata
Title
Bevacizumab/pralsetinib
Various toxicity: case report
Publication date
01-10-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-48280-z

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Multiple drug

Case report

Tocilizumab

Case report

Multiple drugs

Case report

Bortezomib/daratumumab/dexamethasone

Case report

Ocrelizumab

Case report

Fluticasone-propionate/prednisone/salmeterol